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Abstract: Properly working antioxidant defence systems are important for fetal development. One
of the nutrients with antioxidant activity is selenium. Increased maternal selenium intake has been
associated with reduced risk for being small for gestational age and preterm delivery. Based on the
Norwegian Mother, Father, and Child Cohort Study and the Medical Birth Registry of Norway, we in-
vestigated the association of maternal selenium intake from food and dietary supplements during the
first half of pregnancy (n = 71,728 women) and selenium status in mid-pregnancy (n = 2628 women)
with neonatal health, measured as two composite variables (neonatal morbidity/mortality and neona-
tal intervention). Low maternal dietary selenium intake (<30 µg/day) was associated with increased
risk for neonatal morbidity/mortality (adjusted odds ratio (adjOR) 1.36, 95% confidence interval
(95% CI) 1.08–1.69) and neonatal intervention (adjOR 1.16, 95% CI 1.01–1.34). Using continuous
variables, there were no associations between maternal selenium intake (from diet or supplements)
or whole-blood selenium concentration and neonatal outcome in the adjusted models. Our findings
suggest that sufficient maternal dietary selenium intake is associated with neonatal outcome. Adher-
ing to the dietary recommendations may help ensure an adequate supply of selenium for a healthy
pregnancy and optimal fetal development.
Keywords: selenium; neonatal outcome; pregnancy; small for gestational age; Norwegian Mother,
Father, and Child Cohort Study; MoBa; Medical Birth Registry of Norway; MBRN
1. Introduction
Maternal nutrition has been shown to be important for pregnancy and fetal develop-
ment [1,2]. During pregnancy, the continuous physiological changes in the mother and the
development of the fetus are dependent on the supply of specific nutrients [1,3,4]. Both
nutrient deficiency and oversupply have been associated with adverse pregnancy, fetal,
and neonatal outcomes, including preterm delivery, intrauterine growth restriction, and
low birth weight, which are the leading causes of neonatal death [1,2]. Owing to complex
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and diverse biological processes, nutritional requirements and sensitivity to abnormal
nutrient consumption change throughout pregnancy [3]. Understanding the significance of
maternal nutrition can help establish dietary strategies to sustain pregnancy and support
fetal maturation [5].
One of the essential nutrients is the trace element selenium. It plays a role in preventing
cell damage through its antioxidant activity. Selenium, in the form of selenoproteins or antioxi-
dant enzymes, regulates the distribution of reactive oxygen species or free radicals [6,7], thus
preventing oxidative stress. A properly working antioxidant defence system is required
for balancing naturally occurring oxygen tension at different gestational ages [3]. The
lack of oxidative stress regulation has been associated with preeclampsia [8,9], preterm
delivery [10], or small for gestational age (SGA) [11]. Additionally, neonatal health status
has been shown to be dependent on the presence of free radicals [12]. The development of
neonatal morbidities, such as perinatal hypoxic–ischaemic encephalopathy, retinopathy of
prematurity, necrotizing enterocolitis, or bronchopulmonary dysplasia, has been shown to
be related to oxygen free radicals [12].
Previously, our research group detected an association between a single nucleotide
polymorphism in the gene responsible for incorporating selenoproteins (eukaryotic elonga-
tion factor selenocysteine tRNA-specific, EFFSEC) and gestational duration and preterm
delivery (delivery <37 weeks of gestation, PTD), when using selenium at a continuous
rate [13]. The importance of selenium for gestational duration was confirmed in our
population-based epidemiological study [14]. Mothers who had higher dietary selenium
intake during pregnancy had a longer-lasting pregnancy and a decreased risk for preterm
delivery [14]. Similarly, in the same study population, higher dietary selenium intake
was associated with increased birth weight and a reduced risk of SGA (birth weight for
gestational age <10th percentile) [15].
Gestational age at delivery and birth weight are two important determinants of neona-
tal health. Being born too early (PTD) or with too small a birthweight (SGA) is strongly
associated with neonatal mortality or morbidity [16]. Given that we have previously found
maternal selenium intake during pregnancy to be associated with both SGA [15] and
PTD [14], and that it is well know that SGA and PTD are associated with an increased risk
for adverse neonatal outcomes, here, we hypothesized that there may be an association
between maternal selenium intake and impaired neonatal health.
The aim of this study is to examine whether self-reported maternal dietary and sup-
plemental selenium intake during the first half of pregnancy, and maternal selenium status
indicated by whole-blood selenium concentration at week 18, were associated with neona-
tal health assessed in the form of two composite variables: neonatal mortality/morbidity
and neonatal intervention.
2. Materials and Methods
2.1. Data
This study is based on the Norwegian Mother, Father, and Child Cohort Study (MoBa),
which also includes data from the Medical Birth Registry of Norway (MBRN). The MBRN
is a national health registry that contains information about pregnancy, delivery, and the
health of the mother and neonate for nearly all births in Norway since 1967. Through
compulsory notifications, the MBRN collects information about pregnancy, delivery, and
the health of the mother and the neonate. It also contains data from neonatal and paediatric
wards on congenital malformations, neonatal diagnoses, and procedures performed on
infants transferred to those units [17].
MoBa is a population-based, ongoing, prospective pregnancy cohort study conducted
by the Norwegian Institute of Public Health. Voluntarily participating women were
recruited from throughout Norway between 1999 and 2008. Of all the invited women, 41%
consented to participate [18]. The cohort now includes 114,500 children, 95,200 mothers,
and 75,200 fathers. In MoBa, women filled in multiple questionnaires at different time
points during pregnancy and after delivery. In this study, we used data obtained from two
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self-reported questionnaires: the baseline questionnaire (Q1) completed around gestational
week 15 and a food frequency questionnaire (FFQ) completed around gestational week
22. The participants were asked to donate biological samples during pregnancy and at
birth [18]. Blood samples were obtained from both parents during pregnancy and from
mothers and children (umbilical cord) at birth. In this study, we were given access to data
on whole-blood selenium concentration analyzed in a subgroup of participants sampled
during the routine free ultrasound examination at gestational week 18. This study is based
on version 10 of the quality-assured data files released for research in 2017.
The establishment of MoBa and the initial data collection was based on a license from
the Norwegian Data Protection Agency and approval from the Regional Committees for
Medical and Health Research Ethics. The MoBa cohort is now based on regulations related
to the Norwegian Health Registry Act. Written informed consent was obtained from each
participant. The Regional Committees for Medical and Health Research Ethics approved
this study (2015/2425/REK South-East A).
2.2. Study Population
To be included in the current study, women needed to have had responded to the two
first questionnaires (Q1 and FFQ) and to be registered in the MBRN with singleton live
births without congenital malformations (n = 84,855; excluded, n = 29,384). We excluded
pregnancies with gestation lasting <22 weeks and >42 completed weeks (n = 534), and
those with invalid dietary reports (energy intake < 4.5 MJ, > 20 MJ, or > 3 blank pages)
(n = 1493). Among women who participated in MoBa with more than one pregnancy, only
their first enrolled pregnancy was included (excluded, n = 10,925). Finally, we excluded
mother–child pairs with birth weight or selenium intake values that were >4 standard
deviations from the mean (n = 175), resulting in a final study population of n = 71,728 for
the analysis of selenium intake and n = 2628 for the analysis of selenium status. The study
population used in this study was the same as that in our previous selenium study on birth
weight and SGA status [15].
2.3. Maternal Selenium Intake from Food and Dietary Supplements
Maternal daily selenium intake was estimated using the information obtained from
a semiquantitative FFQ developed and validated for use in MoBa [19,20]. The FFQ was
designed to capture dietary habits and intake of dietary supplements during the first
4–5 months of pregnancy. The MoBa FFQ was used from March 2002 through the re-
maining recruitment period. Briefly, women were asked to report their average intake
of 255 different foods and dishes since the beginning of their pregnancy. The frequency
intervals ranged from never to several times daily. The FFQ was validated using a 4-day
food record and biological markers as reference methods. The results showed that the
MoBa FFQ produces a realistic and relatively precise estimate of the habitual intake of
energy, nutrients, and food groups in pregnant Norwegian women, and is a valid tool for
categorizing pregnant women according to high and low intakes of energy, nutrients, and
foods [19–22].
We converted consumption frequencies into food amounts, and calculated the daily
intake of energy and nutrients using FoodCalc [23] and the Norwegian food composition
table [24]. On the last page of the FFQ, the participants were asked to report the use of
dietary supplements by writing the names, brand, intake frequency, and amount [14]. To
calculate the selenium amount contributed by the dietary supplements, we used a database
of dietary supplements [25] and manufacturer-declared nutrient content information. The
selenium from supplements was differentiated into inorganic (selenite and selenate) and
organic (selenomethionine and selenized yeast) forms. Overall, we considered three sources
of selenium: selenium originating from diet, organic selenium from supplements, and
inorganic selenium from supplements.
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2.4. Selenium Status
Maternal blood samples donated in gestational week 18 were shipped via overnight
mail in a vacutainer for long-term freezing in the MoBa biobank repository [26]. Maternal
whole-blood samples from 3000 individuals were retrieved from the biobank in 2015 for
the Human Environmental Biobank project (MoBa Etox) at the Norwegian Institute of
Public Health [27]. Selenium analysis was performed in 2015 at Lund University (Sweden)
using an inductively coupled plasma mass spectrometer (IiCAP Q; Thermo Fisher Scientific
(Bremen) GmbH) equipped with a collision cell having kinetic energy discrimination and
helium as the collision gas. The detection limit was 3.2 µg/L, and the coefficient of variation
was 1.5%. All samples were above the detection limit. The analytical accuracy was verified
against a certified reference material (Seronorm Trace Elements Whole Blood L-1 and L-2;
SERO AS, Billingstad, Norway). Blood sample collection and selenium detection followed
previously detailed procedures [14,15,27].
2.5. Neonatal Outcomes
Data on neonatal outcomes were extracted from the MBRN. Two composite variables for
neonatal outcomes were created: neonatal mortality/morbidity and neonatal intervention.
In terms of neonatal mortality and morbidity outcomes, we included children who
died within 28 days after birth, with 5 min Apgar score < 4, or with any of the following In-
ternational Classification of Disease (10th edition) codes [28]: birth asphyxia (P21), chronic
respiratory disease originating in the perinatal period (P27), intracranial (non-traumatic)
hemorrhage of the fetus and newborn (P52), meconium ileus/necrotizing enterocolitis (P75,
P76, P77, P78.0, P78.1), other disturbances in the cerebral status of newborns (P91.0, P91.1,
P91.2, P91.6), retinopathy of prematurity (H35.1), bacterial sepsis in the newborn (P36), or
other infections specific to the perinatal period (P39).
Neonatal intervention included transfer to the neonatal intensive care unit (NICU), ventila-
tor or continuous positive airway pressure treatment, or treatment with systemic antibiotics.
2.6. Statistical Analyses
We used logistic regression to assess the relationship between different selenium
exposures and neonatal outcomes. Results are provided from both unadjusted and adjusted
models. Potential confounders were obtained from three sources: Q1 (pre-pregnancy
maternal weight, maternal height, maternal education, and smoking during pregnancy),
FFQ (nausea at the time of filling in the FFQ, alcohol consumption, dietary fiber intake,
iodine intake, protein intake, and total energy), and MBRN (maternal age at delivery, and
parity). Maternal weight and height were considered in the form of body mass index
(BMI) according to the World Health Organization classification: <18.5, 18.5–24.9, 25.0–29.9,
or >30.0 kg/m2. Parity was categorized as the number of previous births: 0, 1, 2, or ≥3.
Maternal education was recorded in three strata: <13, 13–16, and >16 years. Smoking was
classified as non-smoking, occasional, or daily smoking. Alcohol consumption, marital
status, nausea, folic acid supplementation, and planned pregnancy were assessed as binary
variables (yes or no). Iodine intake was ranked in quintiles. Dietary fiber, total protein,
total energy intake in kJ, and maternal age at delivery were added as continuous variables.
Women with missing information were removed from the adjusted regression analyses
(66,908 women (93%) had information on all covariates used in the main analyses).
Four different selenium exposures were used: selenium intake from diet, inorganic
selenium intake from supplements, organic selenium intake from supplements, and sele-
nium blood concentration. We conducted the analyses of selenium on a continuous and
dichotomous scale. We standardized (subtracted the mean and divided by the standard
deviation) continuous maternal selenium intake and selenium whole-blood concentration
to determine the risk for neonatal outcomes with increased selenium intake by 1 standard
deviation, which was 14.3 µg/day for dietary selenium intake, 10.4 µg/day for inorganic
selenium from supplements, 33 µg/day for organic selenium from supplements, and
23.4 µg/L for whole-blood selenium concentration. We further assessed the risk of neonatal
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outcomes with respect to total daily selenium intake (selenium from diet and supplements)
<30 and >120 µg. The lower and higher cut-offs are half and double the recommended
daily selenium intake, respectively. In order to assess whether the association between
dichotomized maternal selenium intake and neonatal outcome is mediated by SGA/PTD,
we also estimated the association of total daily maternal selenium intake <30 µg and SGA
status with PTD using logistic regression adjusted for the same set of covariates as the
models for neonatal outcomes. SGA status was defined as birth weight <10th percentile
based on Skajerven’s gestational age-based growth curves [29]. PTD was defined as deliv-
ery <37th week of gestation. IBM SPSS Statistics version 27.0 and R version 3.5.0 were used
to perform the statistical analyses.
3. Results
3.1. Study Population
The selection criteria used in this study resulted in a total of 71,728 mother–child
pairs (84.5% of the 84,855 eligible mothers, i.e., those who had responded to Q1 and
FFQ and were registered in the MBRN with singleton live births) available for the anal-
yses of maternal dietary selenium intake, and 2628 for the analyses of maternal blood
selenium concentration.
Most of the mothers were between 25 and 34 years of age (76%), had >12 years of
education (66%), had a BMI between 18.5 and 29.9 kg/m2 (85%), were never active smokers
(91%) or never passive smokers (88%), and did not drink alcohol (89%) (Table 1). Half of
the women were nulliparous (53%). Nausea in the second trimester was reported by 11%
of women (Table 1).
Higher selenium intake was associated with higher age, education, and parity (Kruskal–
Wallis test, p < 0.001) (Table 1).
Table 1. Dietary intake and total (diet and supplements) selenium intake by maternal characteristics.
Dietary Selenium Intake, µg/day Total Selenium Intake, µg/L
Characteristics n % Median 25th–75thPercentile Median
25th–75th
Percentile
Total population 71,728 100 53 44–62 102 83–123
Maternal age, years <25 8239 11 50 41–61 101 83–125
25–29 24,313 34 52 43–62 101 83–122
30–34 30,410 42 53 45–63 102 84–123
>34 8766 12 54 46–64 104 85–125
Maternal education,
years <12 22,286 31 51 42–62 102 84–125
12–16 29,757 41 53 44–62 101 83–123
>16 18,150 25 54 46–64 102 83–122
Missing 1535 2 51 42–62 99 82–122
Pre-pregnancy BMI,
kg/m2 <18.5 2130 3 53 44–64 103 83–126
18.5–24.9 45,976 64 53 45–63 102 83–123
25–29.9 15,134 21 52 43–61 101 84–123
>30 6633 9 51 42–61 102 84–122
Missing 1855 3 52 44–62 99 81–121
Parity 0 * 38,169 53 52 43–62 102 84–123
1 21,557 30 53 44–62 101 83–122
2 9652 13 54 45–63 101 83–121
≥3 2293 3 54 45–64 104 82–128
Missing 57 1 56 45–63 102 83–115
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Table 1. Cont.
Dietary Selenium Intake, µg/day Total Selenium Intake, µg/L




pregnancy Never 65,504 91 51 42–62 105 83–127
Occasionally 3876 5 53 44–62 102 83–123
Daily 1943 3 52 43–63 102 84–123
Missing 405 1 52 43–62 99 79–121
Passive smoking No 62,767 88 53 44–62 102 83–123
Yes 7580 11 52 43–63 103 83–126
Missing 1381 2 51 43–63 102 83–126
Alcohol consumption No 63,806 89 53 44–62 102 84–123
Yes 7922 11 54 46–63 101 82–122
Nausea during the
second trimester No 63,504 89 53 44–62 102 84–123
Yes 8224 11 52 42–62 100 81–122
Iodine intake, µg/day <89 17,637 25 43 36–50 91 74–112
89–121 17,564 24 50 43–58 98 81–118
121–162 18,354 26 55 48–63 104 87–124
> 162 18,094 25 63 55–73 114 95–135
Protein intake, g/day <76 23,952 33 42 36–48 89 72–108
76–93 23,826 33 65 58–74 114 97–136
>93 23,950 33 53 47–59 101 85–121
Total energy intake,
kJ/day <8392 23,950 33 44 37–50 91 75–112
8392–10,460 23,832 33 63 55–73 112 94–134
>10,460 23,946 33 53 46–60 102 85–121
Gestational age at birth,
weeks + days
≤27 + 6 126 0 53 47–62 114 83–133
28 + 0 to 31 + 6 306 0 50 41–60 98 85–114
32 + 0 to 36 + 6 2836 4 53 44–62 103 86–123
≥37 + 0 67,827 95 53 44–62 102 83–123
Missing 594 1 53 44–62 100 81–120
Birth weight, g <1500 398 1 52 44–62 101 82–121
1500–2500 1751 2 52 43–61 102 86–122
>2500 69551 97 53 44–62 102 83–123
Missing 31 0 52 47–58 107 88–134
The table shows the median daily total selenium intake (from diet and supplements) and selenium intake from diet according to maternal
characteristics in the Norwegian Mother, Father, and Child Cohort Study (n = 71,728). Selenium intake was estimated using a food
frequency questionnaire completed by women at gestational week 22. * Parity refers to the number of births before the current pregnancy
(equal to zero means that the woman had no previous children, primiparous). Abbreviations: BMI, body mass index; n, sample size.
3.2. Selenium Intake
The median selenium intake from diet was 53 µg/day (25th–75th percentile: 44–
62 µg/day). Of the whole study population, 29% met the Nordic recommendation for
selenium for pregnant women of 60 µg/day [30] through dietary intake. Selenium dietary
intake mainly originated from cereals and grains (on average, 41% of total selenium intake),
fish and seafood (29%), meat (23%), and egg and dairy products (20%).
Approximately 33% of women (n = 23,336) reported using selenium-containing dietary
supplements. Of these, 28% took selenium supplementation only in the organic form,
around 4% only in the non-organic form, and 1% in both forms. Women obtaining selenium
from supplements did not differ from women not taking supplements in terms of their
mean dietary selenium intake (54 µg/day in both groups). Supplementation resulted in
a substantially higher total selenium intake (Table 1). The median total selenium intake
(from diet and supplements) was 102 µg (83–123 µg) (Table 1). Of women taking selenium-
containing supplements, 94% met the recommended intake of >60 µg/day [30].
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3.3. Blood Selenium Concentration
The median selenium blood concentration was 105 µg/L (25th–75th percentile: 89–
117 µg/L). Selenium blood concentration was weakly associated with selenium intake
(correlation = 0.11, p < 0.001). Significantly higher blood concentrations of selenium
were found among women taking selenium-containing supplements (110 µg/L, 25th–75th
percentile: 87–115 µg/L) than in women not taking supplements (102 µg/L, 25th–75th
percentile: 94–121 µg/L) (t-test (degrees of freedom): t(46,225), p < 0.001) (Figure 1).
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Figure 1. Sca terplot of selenium concentration in blood and dietary seleniu intake. The figure shows the mean seleniu
concentration in blood in iffere t r s f i t t i l i i t . l i i t (µ day) as
categorized into intervals: 23–27, 28–32, 33–37 up to 120–124, 125–144, and 145–154+. The relationship between intake
and blood concentrations is depicted separately for women who reported using selenium-containing dietary supplements
(black dots) and women who reported no use of such supplements (open dots). Selenium intake among non-supplement
users originated from diet, whereas intake among supplement users is presented as the sum of selenium from diet
and supplements.
3.4. Neonatal Outcomes
In terms of neonatal morbidity, the most common conditions were birth asphyxia
(3.3%) and bacterial sepsis in the newborn (1.3%) (Table 2). A total of 3462 children
(4.8%) had at least one of the selected morbidities or died within 28 days of birth. With
respect to neonatal intervention, NICU admission (15.2%) or the use of systemic antibiotics
(2.8%) were the most common (Table 2). A total of 10,973 children (15.3%) had at least
one intervention.
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Table 2. Number of children included in groups of morbidity or neonatal death and neonatal intervention.




Apgar score < 4 at 5 min 137 0.19
Birth asphyxia (P21) 2416 3.3
Other disturbances in the cerebral status
of the newborn (P910–916) 30 0.04
Intracranial (non-traumatic)
hemorrhage of the fetus and newborn 154 0.21
Retinopathy of prematurity (H351) 22 0.03
Meconium ileus/necrotizing
enterocolitis (P75, P76, P77, P780, P781) 31 0.04
Chronic respiratory disease originating
in the perinatal period (P27) 77 0.11
Bacterial sepsis in the newborn (P36) 906 1.3




Neonatal death 629 0.88
Total neonatal mortality and morbidity 3462 4.83
Neonatal intervention
Systemic antibiotics 1976 2.8
Ventilator 363 0.51
CPAP 935 1.30
NICU admission 10,942 15.25
Total neonatal intervention 10,973 15.30
The table shows the number and percentage of children who died within 28 days after birth or were affected by a
specific morbidity or intervention in the Norwegian Mother, Father, and Child Cohort Study (n = 71,728). The
totals of neonatal mortality and morbidity or neonatal intervention represent the number of children having at
least one diagnosis/intervention. Therefore, the total number is lower than the sum of all diagnoses/interventions.
Abbreviations: ICD-10, International Statistical Classification of Diseases and Related Health Problems, 10th
edition; CPAP, continuous positive airway pressure; NICU, neonatal intensive care unit.
3.5. Selenium Exposure and Neonatal Outcomes
A statistically significant association between selenium derived from supplements
and the composite neonatal outcomes was found only in the three unadjusted models:
inorganic selenium supplements and neonatal mortality and morbidity (OR 1.05 per 10.4
µg/day, 95% CI 1.02–1.08), inorganic selenium supplements and neonatal intervention (OR
1.04 per 10.4 µg/day, 95% CI 1.02–1.06), and selenium blood concentration and neonatal
intervention (OR 1.12 per 23.4 µg/L selenium concentration in whole blood, 95% CI 1.01–
1.25) (Figure 2). The associations were no longer significant after adjusting for potential
confounders (Figure 2).
Total selenium intake < 30 µg/day (2% of all women, observed only among non-
supplement users; Table 3) compared with selenium intake ≥ 30 µg/day was significantly
associated with a higher risk for neonatal mortality/morbidity, in both unadjusted and
adjusted models (adjOR 1.36, 95% CI 1.08–1.69) (Figure 3). After adjustment, total selenium
intake < 30 µg/day was also associated with neonatal intervention (adjOR 1.16, 95% CI 1.01–
1.34) (Figure 3). Total selenium intake < 30 µg/day was not associated with SGA (adjOR
1.14, 95% CI 0.96–1.35) or PTD (adjOR 1.14 95% CI 0.90–1.42) in the adjusted models. Total
selenium intake > 120 µg/day (9% of all women, observed only among supplementing
women; Table 3) compared with selenium intake ≤ 120 µg/day was not associated with
any of the neonatal outcomes in either unadjusted or adjusted models (Figure 3).
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Total selenium intake < 30 µg/day (2% of all women, observed only among non-sup-
plement users; Table 3) compared with selenium intake ≥ 30 μg/day was significantly as-
Figure 2. Associations between maternal selenium intake from diet, selenium intake from dietary supplements, and
blood selenium concentration (all c ntinuous) and ne natal outcomes. The figure presents the ORs and 95% CIs for
neonatal outcomes, neonatal mortality/morbidity (top plot) and neonatal interven i n (bot om plot), per selenium exposure
divided as follows: selenium from di t intake—1 standard deviation of di tary sele ium intake (14.3 µg/day), inorganic
supplements—1 standard deviation of inorganic selenium intake from supplements (10.4 µg/day), organic supplements
1 standard deviation of organic selenium intake from supplements (33.0 µg/day), and 1 standard deviation of selenium
whole-blood concentration (23.4 µg/L). Circles and full dots represent the ORs for the unadjusted and adjusted models,
respectively. Specific ORs and 95% CIs are depicted in the right panel of the figure. Models with maternal selenium
intake from diet or supplementation as exposure were adjusted for maternal age at delivery, maternal pre-pregnancy
body mass index (BMI), parity, maternal smoking during pregnancy, passive smoking, nausea during the second trimester,
matern l educati n, fiber intake, iodi e intake, protein intake, n-3 intake from diet, and total energy intak . M els were
also mutually adjusted for the different sel nium sourc s. Mod ls with maternal selenium concentrati n in whole blood
as exposure w re adjusted for maternal age at delivery, at rnal pre-pregnancy BMI, parity, maternal smoki g uring
pregnancy, passive smoking, and maternal education. The sa ple sizes on which the analyses were run are represented by
the n value in the left panel of the figure. Abbreviations: n, sample size; n-cases, number of cases in each sample; OR, odds
ratio; CI, confidence interval.
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Table 3. Maternal selenium intake from diet and supplements and maternal blood selenium concentration, with respect to neonatal outcomes.
Total, n = 71,728 Neonatal Mortality/Morbidity Neonatal Intervention












µg/day 53 44–62 53 44–62 53 44–62 53 44–62 53 44–62
Inorganic selenium supplements, µg/day 50 35–75 50 35–75 50 36–75 50 35–75 50 36–75
Organic selenium supplements, µg/day 30 21–43 30 21–43 30 25–50 30 21–43 30 21–36
Selenium blood concentration, µg/L 102 89–117 102 89–117 106 89–121 102 89–117 105 92–119
n % n % n % n % n %
Total selenium (diet and
supplements), µg/day
<30 1180 2 1101 2 79 2 976 2 204 2
30–120 64,114 89 61,064 89 3036 88 54,383 90 9731 89
>120 6434 9 6086 9 347 10 5396 8 1038 9
The median daily selenium intake from diet, selenium intake from inorganic or organic supplements, and maternal selenium concentrations in whole blood according to neonatal outcomes in the Norwegian
Mother, Father, and Child Cohort Study (n = 71,728) are shown. The table shows the number and percentage of women with daily selenium intake < 30 µg, between 30 and 120 µg, and >120 µg with respect to
neonatal outcomes. The reported p-values show the significance of the two-tailed t-test.
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4. Discussion
The main finding of this study is an increased risk for at least one of the specified
neonatal interventions or neonatal morbidities, or neonatal death, for babies whose mothers
reported selenium intake <30 µg/day. No association was found between selenium intake
(from diet or supplements, when analyzed as continuous variables), total selenium intake
>120 µg/day or whole-blood selenium concentration and neonatal mortality/morbidity or
neonatal intervention.
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Low maternal serum selenium levels affect maternal antioxidant status, which, in
turn, contributes to the risk of oxidative stress in the neonate [31]. Oxidative stress is asso-
ciated with neonatal morbidities, including retinopathy of prematurity, persistent ductus
arteriosus, necrotizing enterocolitis, intracranial hemorrhage, and hypoxic–ischaemic en-
cephalopathy [31]. In this study, maternal total selenium intake <30 µg/day was associated
with the neonatal composite outcome variables. As with all nutrients, the selenium status
of the fetus is dependent on placental nutrient flow. The placental transfer of selenium is
limited, and the selenium concentration found in umbilical cord blood is approximately
65% of the maternal serum concentration [31,32]. Preterm born infants tend to have lower
serum selenium concentrations in comparison to term infants [31].
In one of our previous studies based on the MoBa cohort, we found a protective
effect of increased maternal dietary selenium intake on SGA (OR 0.92 per 14.3 µg/day
selenium) [15]. In another study in MoBa we found that SGA was associated with mor-
tality/morbidity or neonatal intervention (OR > 3 for both outcomes) [33]. Similarly, we
have previously found increased maternal dietary intake to be associated with a decreased
risk of PTD (hazard ratio (HR) 0.88 per 14.6 µg/day) [14]. PTD is a known risk factor for
neonatal mortality and morbidity [34]. Therefore, we expected to observe a decreased
risk of adverse neonatal outcomes with increased maternal selenium intake, either fully
(Figure 4a) or partly mediated by SGA/PTD (Figure 4b), or with residual confounding
(Figure 4c or Figure 4d). However, we did not find any association between increased
maternal selenium intake (continuous variable) and adverse neonatal outcomes in the
current study. We hypothesize that this lack of association may be due to different types
of SGA/PTD being differently associated with maternal selenium intake and neonatal
outcomes (Figure 4e). Maternal selenium intake might contribute to normal fetal growth
and prevent selenium-related types of SGA/PTD, which may not be associated with the
adverse neonatal outcomes studied (Figure 4e). Conversely, babies born SGA or preterm
owing to reasons other than selenium-related pathological processes might perform worse
and have neonatal morbidities (Figure 4e). As in our previous paper on maternal caffeine
consumption and neonatal outcomes [33], our findings in the current study might support
the hypothesis that babies born SGA or preterm because of different causes might differ in
neonatal health status. Similarly, Hernandez-Diaz proposed an explanation for the higher
death risk in SGA neonates born to non-smoking mothers than in those born to smoking
mothers. They suggested that factors affecting fetal growth and SGA among non-smoking
mothers might be more aggressive than smoking itself, and lead to more serious health
complications [35].
In this study, there was no direct association between higher (>120 µg/day) maternal
total selenium intake and adverse neonatal outcomes. This lack of association might be due
to most of the women having an adequate selenium intake, close to the Nordic recommenda-
tions of 60 ug/day. This level of intake ensures adequate saturation of selenium-dependant
enzymes [36]. Only approximately 6434 (9%) women had daily selenium intake > 120 µg,
and only 139 of them had an intake of > 400 µg/day. Furthermore, higher intake levels
were observed only among women taking supplements.
The major strength of this study is that the analysis is based on a comprehensive
dataset. Adverse neonatal outcomes are rare, which implies that large datasets are needed.
With a sample size of 71,728 mother–child pairs, this study is the largest study examining
the effect of selenium intake from diet and supplements on whole-blood selenium con-
centration and neonatal outcomes. However, we must note that the effects observed are
clinically relevant on the population level, but may not be critical on an individual basis.
As the study included mothers from throughout Norway, the analysis was performed
on mothers who differ in multiple characteristics, such as different areas and regions of
residence, socioeconomic classes, or dietary habits. Detailed questionnaire data and the
MBRN linkage helped us control for major maternal characteristics. The FFQ allowed the
estimation of maternal selenium intake based on a broad set of food items and supplements.
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Neonatal outcomes were retrieved from the national registry (MBRN), guaranteeing that
registration was performed by qualified health-care professionals.
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(c) or SGA/PTD and neonatal outcomes (d); (e) different types of SGA/PTD being differently asso-
ciated with maternal selenium intake and neonatal outcomes. The figure shows four directed acy-
clic graphs displaying the possible associations between maternal selenium intake, SGA, and neo-
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neonatal outcomes. (a) selenium intake effect fully mediated; (b) sel nium intake partially mediated;
resi ual confounding creating spurious association between selenium intake and SGA/PTD (c) or
SGA/PTD and neonatal outcomes (d); (e) different types of SGA/PTD being differently associated
with maternal selenium intake and neonatal outcomes. The figure shows four directed acyclic graphs
displaying the possible associations between maternal selenium intake, SGA, and neonatal outcomes.
Abbreviation: SGA, small for gestational age; PTD, preterm delivery.
The limitations of this study were related to the observational study design. Although
we had information on the major maternal characteristics, we cannot rule out the possibility
that residual or unmeasured confounders exist. Selenium as part of nutrition is effective,
but the effect might be modified by interactions with other nutrients. We acknowledge
that other confounders, such as choline or other nutrients (among others, zinc, vitamins, or
heavy metals), could affect the observed results. However, we adjusted for the lifestyle
factors that can be considered as proxies for several of these confounders.
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In addition, possible self-selection biases might be present. MoBa includes only volun-
tarily participating women who differ from the general population of women giving birth
in Norway in some exposure and outcome characteristics; for example, the participants
are older, better educated, and include fewer smokers. However, a comparison of eight
exposure–outcome associations reported in both MoBa and the MBRN showed no differ-
ences in the selected associations [37]. In addition, the subgroup of women with available
information on whole-blood selenium concentration differs from the MoBa cohort. More
women in this study were non-smokers and had higher education levels than women in
the entire MoBa [27].
Another limitation was that the exposure and outcome variables may be imprecise.
Selenium content varies in plants due to high variety in soil selenium concentrations
and availability, and in meat or dairy products, depending on selenium concentrations
in the fodder, making selenium intake estimation difficult. Additionally, selenium was
estimated using self-reported dietary habits, which are prone to bias. With respect to
neonatal outcomes, the MBRN collects information from maternity units; thus, diagnoses
made after the babies were released from the hospital are missed.
5. Conclusions
Low maternal selenium intake might contribute to adverse neonatal outcomes. Ad-
hering to the dietary recommendations and eating a varied diet will help to ensure an
adequate supply of selenium for a healthy pregnancy and optimal fetal development. We
previously found an association between maternal selenium intake at a continuous rate
and risks for both SGA and PTD, known to be associated with adverse neonatal outcome.
However, in the present study no association was found between continuous selenium
intake or whole-blood selenium concentration and adverse neonatal outcomes. We suggest
that different etiologies of SGA/PTD will lead to different neonatal outcomes; SGA/PTD
associated with maternal selenium intake will have milder adverse neonatal outcomes than
SGA/PTD caused by other, more severe factors.
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